Full-Time

Marketing Automation Administrator

Posted on 9/11/2025

Deadline 1/20/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

Franklin, MA, USA

Hybrid

Hybrid role; 3 days on-site per week (Tue–Thu) in Milford, MA.

Category
Growth & Marketing (2)
,
Required Skills
Agile
Python
JavaScript
Salesforce
JIRA
Data Analysis
HTML/CSS
Requirements
  • Minimum 4+ years of hands-on experience with Marketo (Expert certification required) with prior experience administrating a Marketo instance.
  • Strong understanding of marketing automation, lead lifecycle management, and campaign operations.
  • Strong QA and troubleshooting skills
  • Analytical proficiency as demonstrated by experience with web analytic tools to measure, analyze and report on key performance indicators (KPIs) and ROI
  • Experience with Adobe Experience Cloud applications (Analytics, AEM, CJA, etc), Salesforce (SFDC), and other martech applications (Claravine, AEP, Captello, CVENT, etc)
  • HTML/CSS knowledge for troubleshooting and Javascript and/or python expertise a plus
  • Familiarity with data privacy regulations and governance practices (GDPR, CANSPAM, etc)
  • Excellent communication and stakeholder management skills and the ability to work in a matrixed organization
  • Familiarity with Agile process management tools such as JIRA required
  • Ability to think strategically and execute tactically in a fast-paced environment.
  • Bachelor’s degree in marketing, communications, computer science or other related fields required
Responsibilities
  • Partner with the Marketing Operations team to ensure email campaigns, nurture programs, and lead scoring models run smoothly. Identify, track and implement new ideas to improve workflow and platform efficiency.
  • Responsible for the daily technical operations of Marketo, proactively monitoring system health and swiftly resolving any issues.
  • Provide technical support for email and digital campaigns in Marketo and connected platforms.
  • Offer strategic guidance and enforce best practices in marketing automation.
  • Design and maintain governance frameworks to ensure operational scalability and regulatory compliance.
  • Lead integration efforts across Marketo and related systems (e.g., Adobe Experience Cloud, Salesforce, social and event platforms and other lead capture applications).
  • Champion interoperability across the Martech stack and enable dynamic, personalized campaigns that drive measurable impact.
  • Collaborate with the Marketing Product Owner and Marketing Business Architect to evolve Marketo’s capabilities aligned with strategic goals.
  • Serve as a liaison between technical, operational, and marketing teams to ensure seamless execution.
  • Prioritize the backlog, aligned with the Product Owner, ensuring the most valuable features and enhancements are delivered based on business roadmap and key priorities.
  • Actively participate in agile ceremonies including daily scrums, backlog refinement, and sprint planning.

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
  • Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
  • China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.

What critics are saying

  • Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
  • $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
  • BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.

What makes Waters Corporation unique

  • BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
  • omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
  • ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.

INACTIVE